Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma

Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened t...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Transl Res
Main Authors: Quirk, Shannon K., Shure, Anna K., Agrawal, Devendra K.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609598/
https://ncbi.nlm.nih.gov/pubmed/26118951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trsl.2015.06.005
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker